
Company News
Latest Updates
Product launches, capacity expansions, and partnerships.

New GLP-1 Analog Catalog Line — 50 Ready-to-Ship SKUs
Responding to surging demand in the metabolic disease space, we have launched 50 new GLP-1 receptor agonist analogs available for immediate dispatch in research and GMP grades.

Phase III Manufacturing Suite Now Operational
Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%.

Supply Agreement Signed with Top-5 European Pharma
Monarabiotch has entered a multi-year exclusive supply agreement for three oncology peptide APIs with a leading European pharmaceutical company, valued at over $45M.